A proof-of-concept study of BHV-2100 in the acute treatment of migraine
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs BHV-2100 (Primary)
- Indications Migraine
- Focus Proof of concept; Therapeutic Use
- 20 Jan 2025 New trial record
- 13 Jan 2025 According to Biohaven Pharmaceuticals media release, data from the study expected in 1H 2025.